Verbal Beginnings Opens New Early Intervention Comprehensive Autism Services Center in Alexandria, VA
ALEXANDRIA, Va., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Verbal Beginnings, a premier provider of comprehensive autism services, has officially opened the doors to its newest location in Alexandria, Virginia, serving the greater Northern Virginia area. This cutting-edge center now offers Applied Behavior Analysis (ABA) therapy for children aged 18 months to 6 years. In addition to early intervention ABA services, the center will soon feature Speech-Language Pathology (SLP), Occupational Therapy (OT), and a variety of parent training programs and events, establishing Verbal Beginnings as the top choice for families with children on the Autism Spectrum. Dedicated to individualized care, the center will maintain a 1:1 therapist-to-child ratio, ensuring personalized attention for every child.
Center Highlights
Address: 5290 Shawnee Rd, Suite 101, Alexandria, VA 22312
1:1 Therapist-to-Child Ratio
Accredited Behavioral Health Center of Excellence provider
Certified ACE instruction provider
ACQ-accredited healthcare organization
Indoor and outdoor play areas
Full-Day and Half-Day Program options
Alexandria, VA, is a diverse and family-friendly region home to highly-rated schools and a variety of resources for children of all needs. Verbal Beginnings is proud to serve this vibrant community, offering ABA therapy and support to help children on the autism spectrum reach their fullest potential.
More information is available at: https://www.verbalbeginnings.com/aba-therapy-alexandria-va/
About Verbal BeginningsVerbal Beginnings is a family-focused network of professionals providing exceptional comprehensive autism services to families across the MD, PA, DE, DC and NoVA region. A team of Board Certified Behavior Analysts develop individualized treatment programs to teach and increase communication, feeding, appropriate behavior, social skills, and adaptive living skills. Our team approach ensures that the most progressive techniques are used to meet each child's individual needs. Services include early intervention, feeding therapy, social skills development, after school and summer programs, in-home and center services, Speech and Language Pathology, Occupational Therapy and more. As an ACQ and BHCOE-accredited provider of ABA Therapy, VB is committed to changing lives one child at a time. One professional at a time. www.verbalbeginnings.com
CONTACT: For Media Inquiries Contact: Jon Barnes, VP, Marketing 888.344.5977 marketing@verbalbeginnings.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an R&D Day event for analysts and investors on June 11, 2025 beginning at 9:00 a.m. ET in New York City. Please join members of our management team, including: Michael Davidson, M.D., Chief Executive Officer, John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer, BJ Jones, Chief Commercial Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President. A live webcast of the R&D event will be available and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL CVOT in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP: in to access your portfolio
Yahoo
an hour ago
- Yahoo
Nanoparticles Market is expected to reach USD 120 billion by 2034, driven by a 7.2% CAGR and expanding applications
Nanoparticles Market Overview 2025–2034 Luton, Bedfordshire, United Kingdom, June 05, 2025 (GLOBE NEWSWIRE) -- The global nanoparticles market is witnessing remarkable growth, with its valuation estimated to reach approximately USD 60 billion in 2024, driven by rapid technological innovations and increasing cross-sector applications. Projected to double in size to USD 120 billion by 2034, the market is set to expand at a Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period from 2025 to 2034. The surge in market demand stems from the critical role nanoparticles play across diverse domains such as healthcare, electronics, energy, and environmental science. Download PDF Brochure : Market Drivers and Emerging Trends Nanoparticles have become central to modern innovation, especially in drug delivery systems. Their nano-scale size allows for targeted delivery, enhanced solubility, and increased bioavailability of pharmaceuticals. This utility is particularly vital in oncology, neurology, and cardiovascular therapies. Beyond healthcare, nanoparticles are being adopted extensively in the electronics sector, where they are utilized to improve the conductivity, strength, and durability of semiconductors and display technologies. In the energy sector, their application in battery technologies and solar energy systems is transforming energy storage and conversion processes. Concurrently, growing research and development activities, particularly in nanobiotechnology and nanomedicine, are expected to further stimulate market growth. Governments and private organizations are increasing investments to harness nanoparticles' potential in diagnostics, personalized medicine, and next-generation therapies. Challenges and Market Restraints Despite the promising growth outlook, the nanoparticles market is not without challenges. Regulatory complexities, especially concerning the safety and environmental impact of nanoparticles, remain a critical hurdle. With increasing scrutiny from regulatory bodies, market participants are required to ensure compliance with evolving standards, which can delay product development and commercialization. In addition, supply chain disruptions caused by geopolitical tensions, material scarcity, or trade restrictions can affect raw material availability and production efficiency. Smaller firms in particular may face financial difficulties stemming from price fluctuations and the high cost of nanoparticle research and synthesis. Pricing competition and the need for continual innovation further contribute to the operational pressures faced by manufacturers in this industry. Segmental Insights By Product Type The nanoparticles market is segmented into several product categories, each offering unique performance attributes and commercial potential. Metal-based nanoparticles dominate due to their superior electrical and optical properties, making them highly desirable in catalysis, diagnostics, and electronics. This segment is projected to hold nearly 30% of the total market share. Carbon-based nanoparticles, including graphene and carbon nanotubes, are valued for their strength and electrical conductivity. These materials find widespread applications in electronics, batteries, and structural materials, holding an estimated 25% share of the market. Polymer-based nanoparticles are increasingly used in drug delivery and biomedical applications due to their biocompatibility and controlled release capabilities. This segment is poised to secure approximately 20% of the market. Liposomes and nanocapsules account for 10% of market share and are crucial in enhancing drug solubility and stability. Their role in novel therapeutic formulations is expanding rapidly. Dendrimers and quantum dots, each holding around 5% share, serve niche but high-impact roles in gene therapy, targeted drug delivery, and imaging. Their growth is supported by ongoing research into precision medicine and photonics. By Application Nanoparticles are utilized across a range of industries, with pharmaceuticals representing the largest application area. The pharmaceutical sector commands over 35% of the application share. Nanoparticles enable advanced drug formulations and targeted therapies, supporting the shift towards personalized medicine. The electronics segment, which holds approximately 25% of the market, is expanding rapidly due to the integration of nanoparticles in high-performance components and display technologies. The energy sector contributes about 10%, leveraging nanoparticles for improved battery capacity, fuel cells, and solar panel efficiency. Additional applications are emerging in agriculture, cosmetics, environmental remediation, and the food and beverage industry, each benefitting from the functional enhancements provided by nanoparticles. End-User Industry Insights The healthcare sector is the primary end-user of nanoparticles, holding an estimated 40% market share. This dominance is attributed to the wide application of nanoparticles in therapeutics, imaging, diagnostics, and regenerative medicine. The electronics and semiconductor industry follows closely, accounting for 20% of the demand. Nanoparticles are instrumental in enhancing the performance of microchips, displays, and wearables. The automotive sector, with a 15% share, uses nanoparticles in coatings, battery components, and fuel efficiency improvements. As electric vehicle (EV) production scales up, demand is expected to rise significantly. Other end-user segments include the energy sector (10%), aerospace and defense, textiles, and chemical industries, where nanoparticles contribute to durability, light-weighting, and safety enhancements. Regional Market Analysis In terms of regional performance, North America leads the global nanoparticles market, contributing approximately 40% of total revenue in 2024. The region's robust research infrastructure, supportive regulations, and high concentration of pharmaceutical and biotech companies support its dominance. North America is projected to grow at a CAGR of 8.5% through 2034. The Asia-Pacific region, with an expected 30% market share, is the fastest-growing area with a 10% CAGR. Countries such as China, India, and South Korea are investing heavily in nanotechnology, particularly for electronics, manufacturing, and healthcare. However, regulatory inconsistencies and environmental concerns could hinder market penetration in certain areas. Europe holds around 25% of the market and is characterized by policy-driven sustainability goals and a strong focus on automotive and pharmaceutical innovation. Growth in Europe is forecasted at around 7% CAGR, supported by robust public-private R&D initiatives. Latin America and the Middle East & Africa are emerging markets. While their current market share is relatively small, rising investments in agriculture, environmental solutions, and oil and gas applications point to significant long-term opportunities. These regions must, however, overcome challenges related to funding, infrastructure, and political stability to fully participate in the global nanoparticle revolution. Browse full Report - Market Segmentation Type of Nanoparticles - Metal-based Nanoparticles - Carbon-based Nanoparticles - Polymer-based Nanoparticles - Dendrimers - Liposomes - Nanocapsules - Quantum DotsApplication - Pharmaceuticals - Electronics - Agriculture - Cosmetics - Energy - Environmental - Food and Beverage - BiotechnologyEnd-user Industry - Healthcare - Automotive - Electronics & Semiconductors - Aerospace & Defense - Chemical Industry - Textile Industry - Food Industry - Energy SectorRegion - North America - Europe - Asia-Pacific - Latin America - Middle East & Africa Key Competitors BASF SE Sigma Aldrich (Merck KGaA) Nanosys, Inc. Quantum Materials Corp Nanotech Packaging Co., Ltd. Amgen Inc. Altairnano Pluristem Therapeutics Inc. Tethys Bioscience, Inc. Oxis Energy AstoBio, Inc. QD Vision, Inc. Applied Nanotech Holdings, Inc. Advanced Nano Products Co. Sun Nanotech Buy Now : Recent Developments 1. BASF SE Month/Year: September 2023 Type of Development: Strategic Partnership Detailed Analysis: In September 2023, BASF SE announced a strategic partnership with a major biotech firm aimed at enhancing the application of nanoparticles in drug delivery systems. This collaboration is expected to leverage BASF's advanced materials technology alongside biopharmaceutical advancements to create novel therapeutic solutions. The significance of this partnership lies in its potential to accelerate drug efficacy and reduce side effects, addressing a critical gap in the current pharmaceutical landscape. The integration of nanoparticles into drug delivery systems is poised to bolster market interest, paving the way for enhanced therapeutic effectiveness. As a result, this partnership may shift the competitive landscape, inviting other firms to explore similar collaborations or invest in research and development to stay relevant in an evolving market. 2. Nanosys, Inc. Month/Year: July 2023 Type of Development: Product Launch Detailed Analysis: Nanosys, Inc. launched an innovative product line of quantum dot nanoparticles in July 2023, aimed specifically at enhancing display technologies for consumer electronics. This launch is significant as it positions Nanosys at the forefront of the growing demand for high-performance display solutions. Quantum dot technology plays a pivotal role in next-generation displays, including TVs and smartphones, providing superior color accuracy and energy efficiency. With the consumer electronics industry continuously evolving towards better graphics and lower power consumption, Nanosys's advancements in this area may reshape industry standards. Additionally, this product launch could compel competitors to accelerate their研发 efforts or collaborate with technology companies to incorporate similar advancements, thereby influencing overall market dynamics. 3. Sigma Aldrich (Merck KGaA) Month/Year: June 2023 Type of Development: Acquisition Detailed Analysis: In June 2023, Sigma Aldrich, a division of Merck KGaA, acquired a pioneering company specializing in nanoparticles for environmental applications. This strategic acquisition is seen as a decisive move to expand Sigma Aldrich's portfolio in the sustainable materials sector. The integration of these novel nanoparticles can significantly enhance environmental remediation processes, providing more effective solutions for pollution control. Consequently, this confirms Sigma Aldrich's commitment to sustainability while positioning it to compete strongly in a market increasingly driven by environmental concerns. The acquisition may prompt other companies to reconsider their strategies in terms of sustainability initiatives or partnerships, marking a possible shift toward greener technologies in the nanoparticle sector. 4. Anokiwave, Inc. Month/Year: April 2023 Type of Development: Technological Advancement Detailed Analysis: In April 2023, Anokiwave, Inc. unveiled a breakthrough in microwave technology utilizing advanced nanoparticles to improve signal integrity in communications devices. This development is noteworthy as it represents a leap forward in addressing the limitations posed by traditional materials in telecommunications. The implementation of nanoparticles enhances the performance of communication devices, offering improved bandwidth, efficiency, and overall reliability. As the demand for faster and more efficient communication networks surges globally, Anokiwave's innovation could initiate competitive moves within the telecom sector, encouraging rival firms to invest heavily in similar advancements to maintain competitive advantages. 5. Pluristem Therapeutics Inc. Month/Year: February 2023 Type of Development: Regulatory Approval Detailed Analysis: In February 2023, Pluristem Therapeutics received regulatory approval for its nanoparticle-based cell therapy targeting specific inflammatory diseases. This approval underscores the increasing recognition of the therapeutic potential of nanoparticles in medical treatment. It highlights a significant shift in regulatory bodies' attitudes toward innovative nanoparticle applications in healthcare, paving the way for similar therapies to enter the market. This milestone not only boosts Pluristem's market position but also enhances investor confidence in the viability of nanoparticle technologies in healthcare. The approval may motivate other players in the sector to pursue similar avenues, potentially intensifying competition and sparking a wave of new treatments utilizing nanoparticles across various medical disciplines. This report is also available in the following languages : Japanese (ナノ粒子市場), Korean (나노입자 시장), Chinese (纳米颗粒市场), French (Marché des nanoparticules), German (Markt für Nanopartikel), and Italian (Mercato delle nanoparticelle), etc. Request Sample Pages : More Research Finding – Lipid Nanoparticles LNP Market The global polyurethane (PU) synthetic leather market is estimated to reach a value of approximately $32.4 billion in 2024. The market is projected to grow significantly during the forecast period of 2025–2034, with a projected market value of around $54.7 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of 5.2%. 1 to 50 nm Copper Nanoparticles NPs Market The global synthetic quartz market for semiconductors is projected to reach a value of approximately $1.5 billion in 2024, driven by increasing demand for advanced electronic devices and a shift towards miniaturization in technology. Over the forecast period from 2025 to 2034, the market is expected to expand significantly, reaching an estimated $3.2 billion by 2034, representing a Compound Annual Growth Rate (CAGR) of 8.1%. Zirconium Oxide Nanoparticles Market The global leather rope clamp market is valued at approximately $200 million. The sector is projected to experience steady growth, with an anticipated market value reaching around $350 million by 2034. This represents a Compound Annual Growth Rate (CAGR) of approximately 6.1% during the forecast period from 2025 to 2034. Copper-based Nanoparticles NPs Market The global nylon transfer membranes market is valued at approximately $320 million, driven by increasing demand in biotechnology and pharmaceutical applications. The growing emphasis on efficient filtration and separation processes is propelling market expansion. Between 2025 and 2034, the market is expected to reach $550 million, representing a robust compound annual growth rate (CAGR) of 6.1%. Metal Nanoparticles Market The global laboratory nylon mesh filters market is valued at approximately $300 million, driven by increasing demand for high-purity filtration solutions across pharmaceuticals, biotechnology, and food industries. As researchers prioritize contamination-free results, the market is anticipated to grow significantly during the forecast period from 2025 to 2034, with a projected market value of $520 million. Cerium Oxide Nanoparticles Market The polymer denture material market is valued at approximately $2.1 billion in 2024, with projections indicating a growth trajectory that could reach around $3.5 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period from 2025 to 2034. Dual Therapy Stent Market The global automotive industrial yarns market is valued at approximately $7.8 billion in 2024, with a projected market value of around $12.3 billion by 2034, highlighting a robust growth trajectory. The Compound Annual Growth Rate (CAGR) during the forecast period from 2025 to 2034 is estimated at 4.8%, underscoring the increasing demand for lightweight, durable materials in automotive manufacturing. Distal Radius Plates and Screws Market The global sports compression wear market is valued at approximately $4.5 billion, driven by increasing health awareness and a growing emphasis on athletic performance. The market is projected to reach around $8.6 billion by 2034, demonstrating a Compound Annual Growth Rate (CAGR) of 6.8% during the forecast period from 2025 to 2034. Holographic Foil Market The global single end cord market is valued at approximately $1.5 billion in 2024, driven by increasing demand across various sectors such as textiles, automotive, and electronics. The market is anticipated to reach around $2.5 billion by 2034, reflecting a robust growth trajectory. This growth captures a Compound Annual Growth Rate (CAGR) of approximately 5.3% during the forecast period of 2025 to 2034. High-end Decor Paper Market The global transparent nylon market is valued at approximately $2 billion, driven by increasing demand in sectors like automotive, packaging, and electronics. The market is projected to grow significantly, reaching an estimated value of around $3.5 billion by 2034. This growth translates to a robust Compound Annual Growth Rate (CAGR) of about 5.7% from 2025 to 2034. Expansion Joints in Construction Market The global Dodecanedioic Acid (DDDA) market is valued at approximately $337 million. This market is projected to expand significantly, reaching around $500 million by 2034, driven by increasing demands in industries such as coatings, adhesives, and plastics. The Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is anticipated to be about 4.5%, reflecting a steady growth trajectory fueled by technological advancements and rising applications of DDDA in bio-based materials. Environmental Protection PVC Stabilizer Market The global market for Nylon-MXD6 and m-Xylylenediamine is valued at approximately $500 million. This sector is projected to experience substantial growth, with a forecast market value of around $800 million by 2034. The estimated Compound Annual Growth Rate (CAGR) for the period from 2025 to 2034 is calculated at 5.5%, reflecting a robust uptake driven by increasing demand in industries such as automotive, electronics, and textiles. Biocompatible Materials Market The global market for Nylon 66 chips is projected to reach approximately $6.2 billion in 2024, driven by increasing demand in key sectors such as automotive, electronics, and textiles. The market is expected to grow at a compound annual growth rate (CAGR) of around 5.5%, with an estimated value of $10 billion by 2034. Thin-Film Optical Filters Market The global Nylon 9T market is projected to value approximately $1.2 billion in 2024, driven by increasing demand across automotive, electronics, and consumer goods sectors. As manufacturers prioritize lightweight and durable materials for improved performance, the market is set to grow significantly. The projected market value for the forecast period from 2025 to 2034 is estimated to reach around $2.6 billion. Metallic Foil Market The global nonanediamine and Nylon 9T market is expected to reach a value of approximately $700 million in 2024, driven by increasing demand in industries such as automotive, textiles, and electronics. The market is projected to grow significantly over the next decade, with an estimated value of around $1.2 billion by 2034, reflecting robust opportunities in the development of advanced materials and sustainable practices. Smart Nanomaterials Market The global flat airbag fabric market is valued at approximately $1.2 billion in 2024, fueled by increased demand in automotive safety and innovation in textile technologies. The market is projected to expand at a compound annual growth rate (CAGR) of 7.5%, reaching around $2.3 billion by 2034. Laser Cladding Material Market The global abrasive nylon brush filaments market is valued at approximately $650 million in 2024 and is projected to reach around $1.1 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 5.3% from 2025 to 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Corin Announces the First Clinical Use of Apollo™ for Total Hip Arthroplasty
World-first clinical cases mark the debut of ApolloHipX™—the only THA solution to combine 3D preoperative planning with real-time intraoperative validation from standard fluoroscopy. First Clinical Use of Apollo™ for Total Hip Arthroplasty RAYNHAM, MA, USA, June 05, 2025 (GLOBE NEWSWIRE) -- Corin, a leading innovator in orthopaedics, today announced the first total hip arthroplasty (THA) cases using ApolloHipX™, the newest application for the Apollo™ platform. ApolloHipX™ is the first THA solution to combine dynamic 3D preoperative planning with real-time intraoperative assessment from standard fluoroscopy—enabling surgeons to deliver a personalized plan with precision and efficiency. Dr. Stefan Kreuzer, pioneer in robotic-assisted arthroplasty, performed the first cases using ApolloHipX™ at INOV8 Surgical at Memorial City, the ambulatory surgery center he founded in Houston. 'As a longtime user of OPSInsight™, I've seen how powerful personalized planning can be in improving THA outcomes, particularly when combined with the direct anterior approach to minimize soft-tissue disruption. ApolloHipX™ completes the journey from preoperative planning to intraoperative 3D visualization of that plan with seamless connectivity.' ApolloHipX™ integrates Corin's preoperative planning solution with intraoperative fluoroscopy via proprietary, automated 2D–3D registration software. By aligning a single 2D x-ray with the patient-specific 3D plan, the system provides a real-time 3D assessment of implant position, regardless of patient positioning or C-arm alignment. This streamlined approach to fluoroscopy-based THA reduces the number of intraoperative images required*, minimizing surgical time and radiation exposure within the OR. 'Corin is a leader in recognizing the impact of spinopelvic mobility on THA outcomes, and ApolloHipX™ brings those insights into the OR,' said Dr. Jim Pierrepont, Global Franchise Lead at Corin. 'Traditionally, achieving surgical precision through technology has come at the cost of added time, complexity, or workflow disruption. ApolloHipX™ changes that, delivering accurate, personalized 3D guidance without compromising efficiency.' Apollo™ was built from the ground up as a connected surgical ecosystem—integrating AI-driven planning, intraoperative tools, and cloud-based analytics to support more consistent, personalized orthopaedic care. ApolloKnee™, introduced in 2024, brought pre-resection balance assessment into the operating room with BalanceBot™, enabling data-driven implant decisions before bone cuts are made. ApolloHipX™ now extends that same intelligent foundation to total hip arthroplasty, offering real-time 3D validation within a streamlined, fluoroscopy-based workflow. ApolloHipX™ is available through a limited market release, for more information, please visit or contact your local Corin representative. Not all products are available or cleared for distribution in all markets. About Corin: Corin is a fast-growing global leader in orthopaedic innovation, with a vision to revolutionize the field. By integrating advanced robotic and AI technologies for planning, implementation, and continuous learning with its clinically proven implants, Corin strives to maximize healthcare value for both patients and providers. *Arulampalam, J., Ehlke, M.F., Plaskos, C. et al. Accuracy of a novel, automated 2D-3D registration software for measuring cup position in total hip arthroplasty. Int J CARS (2025). Attachment First Clinical Use of Apollo™ for Total Hip Arthroplasty CONTACT: Molly MacLennan Corin Group 774-226-1853 media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
